Sionna Therapeutics (NASDAQ:SION) Posts Earnings Results, Misses Estimates By $0.08 EPS

Sionna Therapeutics (NASDAQ:SION) released its quarterly earnings results on Tuesday. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08), FiscalAI reports.

Sionna Therapeutics Stock Up 0.9%

Shares of NASDAQ SION traded up $0.38 on Thursday, hitting $43.50. The company had a trading volume of 106,531 shares, compared to its average volume of 345,574. Sionna Therapeutics has a 12-month low of $11.77 and a 12-month high of $48.44. The business has a 50 day moving average of $39.11 and a two-hundred day moving average of $39.51. The firm has a market capitalization of $1.96 billion, a P/E ratio of -22.43 and a beta of 1.35.

Insider Transactions at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the transaction, the director owned 3,247,025 shares in the company, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,717,760 shares of company stock valued at $77,562,902. 3.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SION. Goldman Sachs Group Inc. purchased a new position in shares of Sionna Therapeutics during the 1st quarter valued at approximately $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics during the 1st quarter worth approximately $837,000. Geode Capital Management LLC raised its position in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the period. Rhumbline Advisers acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $307,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $118,000.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on SION shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Guggenheim boosted their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Wedbush initiated coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.00.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.